Sign in Subscribe

msi-h

A collection of 92 issues

DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC A new study identifies the dihydropyrimidine dehydrogenase (DPD) metabolic pathway as the first predictor of immune checkpoint inhibitor efficacy in MSI-H tumors, potentially helping identify patients at risk for resistance. (Journal for ImmunoTherapy

CRC Research Update — August 15, 2026

Today's colorectal cancer research highlights

Multimodal deep learning model predicts MSI status from CT and pathology

Skip to content The CRC Digest Multimodal deep learning model predicts MSI status from CT and pathology Researchers developed a multimodal deep learning model integrating CT radiomics and histopathologic pathomics for predicting microsatellite instability in colorectal cancer, enrolling 509 patients from two medical centers. (Academic Radiology) This content is informational

CRC Research Update — August 13, 2026

Today's colorectal cancer research highlights

Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer An indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4

Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC

Skip to content The CRC Digest Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC A Chinese study used a three-state partitioned survival model to evaluate nivolumab plus ipilimumab versus nivolumab monotherapy in previously treated metastatic colorectal cancer patients with dMMR/MSI-H, using Kaplan-Meier curves

CRC Research Update — August 09, 2026

Today's colorectal cancer research highlights

Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC A study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)

CRC Research Update — August 08, 2026

Today's colorectal cancer research highlights

AI method for classifying pathology whole slide images using self-distillation technique

Skip to content The CRC Digest ◇ RESEARCH AI method for classifying pathology whole slide images using self-distillation technique Researchers developed a phenotypic self-distillation approach to classify whole slide images in colorectal cancer, addressing limitations of current attention mechanisms in Multiple Instance Learning. (Pathology Research and Practice) This content is informational